PriceTargets.com logo

Fortrea - FTRE Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $37.29
  • Forecasted Upside: 2.57%
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$36.35 As of 04/26/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for FTRE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fortrea Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FTRE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FTRE

Analyst Price Target is $37.29
▲ +2.57% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Fortrea in the last 3 months. The average price target is $37.29, with a high forecast of $44.00 and a low forecast of $27.00. The average price target represents a 2.57% upside from the last price of $36.35.

This chart shows the closing price for FTRE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 8 polled investment analysts is to hold stock in Fortrea. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
2/3/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
5/4/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
8/2/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
10/31/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
1/29/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
3/29/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
4/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2024Robert W. BairdInitiated CoverageNeutral$43.00Low
3/6/2024Deutsche Bank AktiengesellschaftInitiated CoverageHold$36.00N/A
1/25/2024BarclaysLower TargetOverweight ➝ Overweight$38.00 ➝ $35.00Low
1/5/2024William BlairInitiated CoverageMarket PerformLow
1/4/2024Jefferies Financial GroupInitiated CoverageBuy$44.00Low
12/11/2023CitigroupUpgradeNeutral ➝ Buy$34.00 ➝ $40.00Low
12/1/2023Evercore ISIUpgradeIn-Line ➝ Outperform$32.00 ➝ $36.00Low
11/14/2023BarclaysUpgradeEqual Weight ➝ Overweight$29.00 ➝ $38.00Low
10/19/2023CitigroupInitiated CoverageNeutral$32.00Low
10/11/2023Evercore ISILower Target$31.00 ➝ $30.00Low
9/14/2023Evercore ISIInitiated CoverageInline$31.00Low
8/15/2023BarclaysInitiated CoverageEqual Weight$29.00Low
8/7/2023Bank of AmericaInitiated CoverageUnderperform$27.00Low
(Data available from 4/28/2019 forward)

News Sentiment Rating

1.37 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2023
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/31/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2023
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2024
  • 7 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
3/29/2024
  • 16 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/28/2024

Current Sentiment

  • 16 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Fortrea logo
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $36.35
Low: $36.13
High: $37.07

50 Day Range

MA: $37.92
Low: $35.39
High: $40.28

52 Week Range

Now: $36.35
Low: $24.92
High: $41.02

Volume

413,403 shs

Average Volume

751,729 shs

Market Capitalization

$3.25 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Fortrea?

The following Wall Street research analysts have issued stock ratings on Fortrea in the last twelve months: Bank of America Co., Barclays PLC, Citigroup Inc., Deutsche Bank Aktiengesellschaft, Evercore ISI, Jefferies Financial Group Inc., Robert W. Baird, and William Blair.
View the latest analyst ratings for FTRE.

What is the current price target for Fortrea?

7 Wall Street analysts have set twelve-month price targets for Fortrea in the last year. Their average twelve-month price target is $37.29, suggesting a possible upside of 2.6%. Jefferies Financial Group Inc. has the highest price target set, predicting FTRE will reach $44.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $27.00 for Fortrea in the next year.
View the latest price targets for FTRE.

What is the current consensus analyst rating for Fortrea?

Fortrea currently has 1 sell rating, 3 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in FTRE, but not buy more shares or sell existing shares.
View the latest ratings for FTRE.

What other companies compete with Fortrea?

Other companies that are similar to Fortrea include RadNet, Guardant Health, Veracyte, Exact Sciences and Natera. Learn More about companies similar to Fortrea.

How do I contact Fortrea's investor relations team?

Fortrea's physical mailing address is 8 Moore Drive, Durham, NC 27709, United States, . The company's listed phone number is 877-495-0816 and its investor relations email address is [email protected]. The official website for Fortrea is www.fortrea.com. Learn More about contacing Fortrea investor relations.